Company Overview - Maravai LifeSciences, Inc. is a global provider of life science reagents and services, focusing on supporting researchers and biotech innovators [3] - The company specializes in critical products for drug therapies, diagnostics, and novel vaccines, and supports research on human diseases [3] Upcoming Financial Results - Maravai plans to announce its second quarter 2025 financial and operating results after market close on August 11, 2025 [1] - A conference call and webcast will be held on the same day at 2:00 p.m. PT/5:00 p.m. ET [1] Conference Call Participation - Participants can join the conference call by dialing (800) 267-6316 or (203) 518-9783, referencing Conference ID MARAVAI [2] - The call will also be available via live or archived webcast on the Maravai website [2]

Core Viewpoint - Maravai LifeSciences Holdings, Inc. reported disappointing fourth-quarter 2024 earnings, missing analyst expectations and facing a significant price target downgrade due to concerns over its financial outlook and ongoing legal issues [1][4]. Financial Performance - The company posted an adjusted loss per share of $0.06, which was wider than the expected loss of $0.04, with quarterly revenue at $56.6 million, slightly below the consensus forecast of $56.67 million [2]. - For the full year, Maravai reported revenue of $259 million, consistent with its guidance, but its GAAP net loss widened to $260 million from a $138 million loss in 2023 [3]. Analyst Reactions - Following the disappointing results, Stifel analysts reduced their price target for Maravai by 50%, from $10.00 to $5.00, reflecting concerns about the company's near-term financial outlook and weaker-than-expected revenues and EBITDA [4]. Legal Issues - Maravai is facing a securities class action lawsuit alleging improper accounting practices, including failure to disclose significant financial issues and misleading statements [5]. - The lawsuit claims that Maravai's stock price fell nearly 22% after the company announced a delay in its fiscal 2024 earnings release due to the need for more time to complete its financial close [5]. Accounting Concerns - CFO Kevin Herde acknowledged errors in revenue recognition, specifically a $3.9 million misrecording due to timing issues related to a shipment [6]. - The company also recorded an $11.9 million non-cash goodwill impairment charge related to its Alphazyme acquisition, indicating material weaknesses in internal controls over revenue recognition and goodwill assessments [7][9].

Company Overview - Maravai LifeSciences, Inc. is a global provider of life science reagents and services, supporting researchers and biotech innovators [3] - The company specializes in products for drug therapies, diagnostics, and novel vaccines, and supports research on human diseases [3] - Maravai's offerings include nucleic acid synthesis and biologics safety testing, serving leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [3] Upcoming Financial Announcement - Maravai plans to announce its first quarter 2025 financial and operating results after market close on May 12, 2025 [1] - A conference call and webcast will be held on the same day at 2:00 p.m. PT / 5:00 p.m. ET [1] Conference Call Participation - Participants can join the conference call by dialing (800) 343-4849 or (203) 518-9848, referencing Conference ID MARAVAI [2] - The call will also be available via live or archived webcast on the Maravai website [2]